Oncology Research and Treatment
Original Article · Originalarbeit
Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) ExperienceCetin B.a · Benekli M.a · Oksuzoglu B.b · Koral L.c · Ulas A.b · Dane F.d · Turker I.b · Kaplan M.A.e · Koca D.f · Boruban C.c · Yilmaz B.g · Sevinc A.h · Berk V.i · Isıkdogan A.e · Uncu D.j · Harputluoglu H.k · Coskun U.a · Buyukberber S.aaDepartment of Medical Oncology, Gazi University Faculty of Medicine, bDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, cDepartment of Medical Oncology, Selcuk University Meram Faculty of Medicine, Konya, dDepartment of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, eDepartment of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, fDepartment of Medical Oncology, Dokuz Eylul University Faculty of Medicine, Izmir, gDepartment of Medical Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Istanbul, hDepartment of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, iDepartment of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, jDepartment of Medical Oncology, Numune Training and Research Hospital, Ankara, kDepartment of Medical Oncology, Inonu University Faculty of Medicine, Malatya, Turkey
Bulent Cetin, M.D Division of Medical Oncology Department of Internal Medicine Gazi University Faculty of Medicine Besevler, Ankara 06500, Turkey caretta06@hotmail.com |
|
Abstract
Background: We investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) treated with lapatinib and capecitabine (LC). Patients and Methods: A total of 203 patients with HER2+ MBC, who had progressed after trastuzumab-containing chemotherapy, were retrospectively evaluated in 11 centers between September 2009 and May 2011. 85 patients who had developed BMs before the initiation of treatment with LC were included. All patients had received prior cranial radiotherapy. All patients were treated with the combination of lapatinib (1,250 mg/day continuously) and capecitabine (2,000 mg/m2 on days 1–14 of a 21-day cycle). Results: The median follow-up was 10.5 months (range 1–38 months). An overall response rate of 27.1% was achieved, including complete response in 2 (2.4%) and partial response in 21 (24.7%) patients. Median progression-free survival was 7 months (95% confidence interval (CI) 5–9), with a median overall survival of 13 months (95% Cl 9–17). The most common side effects were hand-foot syndrome (58.8%), nausea (55.3%), fatigue (48.9%), anorexia (45.9%), rash (36.5%), and diarrhea (35.4%). Grade 3–4 toxicities were hand-foot syndrome (9.4%), diarrhea (8.3%), fatigue (5.9%), and rash (4.7%). There were no symptomatic cardiac events. Conclusion: LC combination therapy was effective and well-tolerated in patients with HER2+ MBC with BMs, who had progressive disease after trastuzumab-containing therapy.
Related Articles:
Article / Publication Details
Published online: October 31, 2012
Issue release date: December 2012
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0
ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)
For additional information: https://www.karger.com/ORT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
